The retinoic acid and brain-derived neurotrophic factor differentiated SH-SY5Y cell line as a model for Alzheimer's disease-like tau phosphorylation

Biochemical and Biophysical Research Communications

Volumn 319, Issue 3, 2004, Pages 993-1000

  Jämsä, Anne ^a,b   Hasslund, Kristina ^b   Cowburn, Richard F ^a   Bäckström, Anders ^b   Vasänge, Mervi ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Cdk5; GSK3 ; JNK; Lithium; SH SY5Y cells

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN PROTEIN; CYCLIN DEPENDENT KINASE 5; ENZYME INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR; LITHIUM; PROTEIN KINASE; RETINOIC ACID; SERINE; STRESS ACTIVATED PROTEIN KINASE; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; CELL DIFFERENTIATION; CELL ULTRASTRUCTURE; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; ENZYME INHIBITION; HUMAN; HUMAN CELL; NERVE FIBER GROWTH; NEUROFIBRILLARY TANGLE; NEUROPHYSIOLOGY; PATHOPHYSIOLOGY; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION;

ALZHEIMER DISEASE; BRAIN-DERIVED NEUROTROPHIC FACTOR; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL SIZE; CYCLIN-DEPENDENT KINASE 5; CYCLIN-DEPENDENT KINASES; GLYCOGEN SYNTHASE KINASE 3; GROWTH INHIBITORS; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; NEUROFIBRILLARY TANGLES; PHOSPHORYLATION; PURINES; SERINE; TAU PROTEINS; TRETINOIN;

EID: 2942623972     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2004.05.075     Document Type: Article

References (33)

1. Grundke-Iqbal I., Iqbal K., Tung Y.C., Quinlan M., Wisniewski H.M., Binder L.I. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. 83:1986;4913-4917
2. Kosik K.S., Joachim C.L., Selkoe D.J. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc. Natl. Acad. Sci. 83:1986;4044-4048
3. Alonso A.C., Grundke-Iqbal I., Barra H.S., Iqbal K. Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau. Proc. Natl. Acad. Sci. 94:1997;298-303
4. Yamaguchi H., Ishiguro K., Uchida T., Takashima A., Lemere C.A., Imahori K. Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3 beta and cyclin-dependent kinase 5, a component of TPK II. Acta Neuropathol. (Berl). 92:1996;232-241
5. Pei J.J., Tanaka T., Tung Y.C., Braak E., Iqbal K., Grundke-Iqbal I. Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J. Neuropathol. Exp. Neurol. 56:1997;70-78
6. Pei J.J., Braak E., Braak H., Grundke-Iqbal I., Iqbal K., Winblad B., Cowburn R.F. Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J. Neuropathol. Exp. Neurol. 58:1999;1010-1019
7. Patrick G.N., Zukerberg L., Nikolic M., de la Monte S., Dikkes P., Tsai L.H. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature. 402:1999;615-622
8. Lee K.Y., Clark A.W., Rosales J.L., Chapman K., Fung T., Johnston R.N. Elevated neuronal Cdc2-like kinase activity in the Alzheimer disease brain. Neurosci. Res. 34:1999;21-29
9. Tseng H.C., Zhou Y., Shen Y., Tsai L.H. A survey of Cdk5 activator p35 and p25 levels in Alzheimer's disease brains. FEBS Lett. 523:2002;58-62
10. Pei J.J., Grundke-Iqbal I., Iqbal K., Bogdanovic N., Winblad B., Cowburn R.F. Accumulation of cyclin-dependent kinase 5 (cdk5) in neurons with early stages of Alzheimer's disease neurofibrillary degeneration. Brain Res. 797:1998;267-277
11. Zhu X., Raina A.K., Rottkamp C.A., Aliev G., Perry G., Boux H., Smith M.A. Activation and redistribution of c-jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. J. Neurochem. 76:2001;435-441
12. Augustinack J.C., Schneider A., Mandelkow E.M., Hyman B.T. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol. (Berl). 103:2002;26-35
13. Liu F., Iqbal K., Grundke-Iqbal I., Gong C.X. Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta. FEBS Lett. 530:2002;209-214
14. Reynolds C.H., Utton M.A., Gibb G.M., Yates A., Anderton B.H. Stress-activated protein kinase/c-jun N-terminal kinase phosphorylates tau protein. J. Neurochem. 68:1997;1736-1744
15. Lau L.F., Schachter J.B., Seymour P.A., Sanner M.A. Tau protein phosphorylation as a therapeutic target in Alzheimer's disease. Curr. Top. Med. Chem. 2:2002;395-415
16. Encinas M., Iglesias M., Liu Y., Wang H., Muhaisen A., Cena V., Gallego C., Comella J.X. Sequential treatment of SH-SY5Y cells with retinoic acid and brain-derived neurotrophic factor gives rise to fully differentiated, neurotrophic factor-dependent, human neuron-like cells. J. Neurochem. 75:2000;991-1003
17. Kaplan D.R., Matsumoto K., Luracelli E., Thiele C.J. Induction of TrkB by retinoic acid mediates biologic responsiveness to BDNF and differentiation of human neuroblastoma cells. Neuron. 11:1993;321-331
18. Encinas M., Iglesias M., Llecha N., Comella J.X. Extracellular-regulated kinases and phosphatidylinositol 3-kinase are involved in brain-derived neurotrophic factor-mediated survival and neuritogenesis of the neuroblastoma cell line SH-SY5Y. J. Neurochem. 73:1999;1409-1421
19. Goedert M., Jakes R. Expression of separate isoforms of human tau proteins: correlation with the tau pattern in brain and effects on tubulin polymerisation. EMBO J. 9:1990;4225-4230
20. Mai L., Jope R.S., Li X. BDNF-mediated signal transduction is modulated by GSK3beta and mood stabilizing agents. J. Neurochem. 82:2002;75-83
21. Sadot E., Jaaro H., Seger R., Ginzburg I. Ras-signaling pathways: positive and negative regulation of tau expression in PC12 cells. J. Neurochem. 70:1998;428-431
22. S. Paccioretti, D. Uberti, M. Memo, A novel in vitro model of human neurons to study tau abnormal post-transcriptional modification, Alzheimer's and Parkinson's Disease Sixth International Conference, Book of Abstracts (2003) p. 31
23. Brion J.P., Octave J.N., Couck A.M. Distribution of the phosphorylated microtubule-associated protein tau in developing cortical neurons. Neuroscience. 63:1994;895-909
24. Brion J.P., Smith C., Couck A.M., Gallo J.M., Anderton B.M. Developmental changes in tau phosphorylation: fetal tau is transiently phosphorylated in a manner similar to paired helical filament-tau characteristic of Alzheimer's disease. J. Neurochem. 61:1993;2071-2080
25. Tokuoka H., Saito T., Yorifuji H., Wei F., Kishimoto T., Hisanaga S. Brain-derived neurotrophic factor-induced phosphorylation of neurofilament-H subunit in primary cultures of embryo rat cortical neurons. J. Cell Sci. 113:2000;1059-1068
26. Liu Z.G., Lewis J., Wang T.H., Cook A. Role of c-Jun N-terminal kinase in apoptosis. Methods Cell Biol. 66:2001;187-195
27. Mielke K., Damm A., Yang D.D., Herdegren T. Selective expression of JNK isoforms and stress-specific JNK activity in different neural cell lines. Brain Res. Mol. Brain Res. 75:2000;128-137
28. Lovestone S., Reynolds C.H. The phosphorylation of tau: a critical stage in neurodevelopment and neurodegenerative processes. Neuroscience. 78:1997;309-324
29. Klein P.S., Melton D.A. A molecular mechanism for the effect of lithium on development. Proc. Natl. Acad. Sci. 93:1996;8455-8459
30. Meijer L., Borgne A., Mulner O., Chong J.P., Blow J.J., Inagaki N., Inagaki M., Delcros J.G., Moulinoux J.P. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem. 243:1997;527-536
31. Bennett B.L., Sasaki D.T., Murray B.W., O'Leary E.C., Sakata S.T., Xu W., Leisten J.C., Motiwala A., Pierce S., Satoh Y., Bhagwat S.S., Manning A.M., Anderson D.W. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. 98:2001;13681-13686
32. Takahashi M., Yasutake K., Tomizawa K. Lithium inhibits neurite growth and tau protein kinase I/glycogen synthase kinase-3beta-dependent phosphorylation of juvenile tau in cultured hippocampal neurons. J. Neurochem. 73:1999;2073-2083
33. Guise S., Braguer D., Carles G., Delacourte A., Briand C. Hyperphosphorylation of tau is mediated by ERK activation during anticancer drug-induced apoptosis in neuroblastoma cells. J. Neurosci. Res. 63:2001;257-267